Get started
Work

Tirzepatide for Severe Obesity in Adolescents Without Diabetes

Year: 2026
Type: article
Study design: Case Report
Abstract: Background/Objective: Tirzepatide, a dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist, has demonstrated substantial weight reduction in adults but remains unapproved for obesity treatment in adolescents without diabetes. The objective of this report is to describe adolescents with severe obesity without diabetes treated with tirzepatide, highlighting body mass index reduction (BMI), metabolic outcomes, and tolerability in a safety-net setting. Case Presentation: decreased across all patients, with reductions from baseline to 18 months of 190% to 158%, 200% to 145%, 150% to 85%, and 135% to 85%; one patient decreased from 125% to 85% by 12 months. These changes corresponded to absolute weight reductions of 17.6 to 40 kg (13%-36%). Hemoglobin A1c decreased or remained within the normal range (4.3%-5.6%), triglycerides declined, and alanine aminotransferase normalized. No hypoglycemia or pancreatitis occurred. No treatment discontinuations were documented during available follow-up. Discussion: Marked weight reduction and metabolic improvement observed in these youth with obesity, without type 2 diabetes are consistent with outcomes reported in adult populations receiving tirzepatide, with greater weight loss associated with improved cardiometabolic parameters. Conclusion: This series highlights substantial weight reduction among adolescents with severe obesity treated with tirzepatide. Participants tolerated therapy during observed follow-up without reported gastrointestinal adverse effects, supporting further investigation in pediatric populations.
DOI: 10.1016/j.aed.2026.07.013
Language: English
Field: Medicine
Open Access status: hybrid
OpenAlex ID: W7171997055
FWCI:
Cites: 14
Cited by:
Related to: 10